CLO Christine Bellon sells 18,629 shares at $34.61 avg; holds 97,038 shares post-sale in unprofitable BEAM
Christine Bellon, Chief Legal Officer of Beam Therapeutics, executed 3 separate sales totaling 18,629 shares for $644,831.51 at a blended average price of $34.61 on 2026-01-15, reducing her holdings by 16.1% to 97,038 shares. The sales were priced near the 52-week high of $35.41, occurring while the stock has risen 16.5% over 30 days and 11.8% over 90 days. Beam Therapeutics remains unprofitable with a net income of $-112,728,000.00 for the latest fiscal year and revenue that declined 83.2% annually, characteristics that typically warrant executive scrutiny. The volume and timing of this multi-transaction sale merit monitoring given the company's financial deterioration and the insider's legal responsibilities as CLO.